References

  1. WHO, Report of the sixteenth meeting of the who alliance for the elimination of blinding trachoma by 2020. http://www.who.int/blindness/publications/GET16Report.pdf. Accessed on 2/03/2013. 2012.

  2. Resnikoff S, et al. Global data on visual impairment in the year 200 Bulletin of the World Health Organization. 2004; 82(11): 844-851. PubMed | Google Scholar

  3. Emerson PM, et al. The SAFE strategy for trachoma control: Using operational research for policy, planning and implementation. Bulletin of the World Health Organization. 2006; 84(8): 613-9. PubMed | Google Scholar

  4. WHO, Report of the Third Meeting of the WHO Alliance for the Global Elimination of Trachoma, Ouarzazate, Morocco, 19–20 October 1998 (unpublished document WHO/PBL/GET/99.3) Geneva, World Health Organization, 1999 (available at: http://wholibdoc.who.int/hq/1999/WHOPBLGET99.3pdf). 1998.

  5. Karimurio J, IF, Gichangi M. Trachoma control using the who adopted "safe with azithromycin". East Afr Med J. 2007 Mar;84(3):127-3 2007. PubMed | Google Scholar

  6. MPH&Sanitation. Overview of the trachoma situation in Kenya, Trachoma desk. Ministry of Public Health and Sanitation. 2011. Google Scholar

  7. Biebesheimer JB et al. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. Ophthalmology. 2009; 116(11): 2047-50. PubMed | Google Scholar

  8. World Health Organization. Trachoma control A guide for programme managers. 2006, Geneva. Google Scholar

  9. Cromwell EA, et al. Monitoring of mass distribution interventions for trachoma in Plateau State, Nigeria. PLoS Negl Trop Dis. 2013; 7(1): e1995. PubMed | Google Scholar

  10. Chidambaram JD et al. Effect of a Single Mass Antibiotic Distribution on the Prevalence of Infectious Trachoma. JAMA. 2006; 295(10): 1142-1146. PubMed | Google Scholar

  11. Ngondi J et al. Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet. 2006; 368(9535): 589-95. PubMed | Google Scholar

  12. Schachter J et al. Azithromycin in control of trachoma. Lancet. 1999; 354(9179): 630-5. PubMed | Google Scholar

  13. Solomon AW et al. Mass Treatment with Single-Dose Azithromycin for Trachoma. New England Journal of Medicine. 2004; 351(19): 1962-1971. PubMed | Google Scholar

  14. Porco TC et al. Effect of Mass Distribution of Azithromycin for Trachoma Control on Overall Mortality in Ethiopian Children: A Randomized Trial. JAMA. 2009; 302(9): 962-968. PubMed | Google Scholar

  15. Keenan JD et al. Childhood Mortality in a Cohort Treated With Mass Azithromycin for Trachoma. Clin Infect Dis. 2011 Apr 1;52(7):883-8. PubMed | Google Scholar

  16. Chidambaram JD et al. Mass antibiotic treatment and community protection in trachoma control programs. Clin Infect Dis. 2004; 39(9): e95-7. PubMed | Google Scholar

  17. Haug S et al. The Decline of Pneumococcal Resistance after Cessation of Mass Antibiotic Distributions for Trachoma. Clinical Infectious Diseases. 2010; 51(5): 571-574. PubMed | Google Scholar

  18. Fry, AÂ M et al. Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal. Clinical Infectious Diseases. 2002; 35(4): p. 395-402. PubMed | Google Scholar

  19. Coles, CL et al. Mass Distribution of Azithromycin for Trachoma Control Is Associated With Increased Risk of Azithromycin-Resistant Streptococcus pneumoniae Carriage in Young Children 6 Months After Treatment. Clin Infect Dis. Clin Infect Dis. 2013 Jun;56(11):1519-26. PubMed | Google Scholar

  20. WHO, WHO factsheet 2008 (Updated June 2011):The top 10 causes of death. http://who.int/mediacentre/factsheets/fs310/en/. Accesed on 9/10/2013. 2008.

  21. Lim, SS et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380(9859): 2224-60. PubMed | Google Scholar

  22. Snow RW, Korenromp EL and Gouws E. pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg. 2004; 71(2suppl): 16-24. Google Scholar

  23. otez, PJ et al. Control of Neglected Tropical Diseases. New England Journal of Medicine. 2007; 357(10): 1018-1027. PubMed | Google Scholar

  24. Hotez, PJ. Mass Drug Administration and Integrated Control for the World's High-Prevalence Neglected Tropical Diseases. Clin Pharmacol Ther. 2009; 85(6): 659-664. PubMed | Google Scholar

  25. Molyneux DH, Hotez PJ, and Fenwick A. "Rapid-Impact Interventions": How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the Poor. PLoS Med. 2005; 2(11): e336. PubMed | Google Scholar

  26. Reddy M, et al. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA. 2007; 298(16): 1911-24. PubMed | Google Scholar

  27. El-Tahtawy A, et al. The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008; 2(5): e236. PubMed | Google Scholar

  28. Snider LA, et al. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry. 2005; 57(7): 788-92. PubMed | Google Scholar

  29. Balicer RD, et al. Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination. Vaccine. 2010; 28(34): 5591-5596. PubMed | Google Scholar

  30. Thomas RJ, et al. Penicillin Prophylaxis for Streptococcal Infections in United States Navy and Marine Corps Recruit Camps, 1951-1985. Rev of Infect Diseases. 1988;10(1): 125-1. PubMed | Google Scholar

  31. Guchev IA, Gray GC and Klochkov OI. Two Regimens of Azithromycin Prophylaxis against Community-Acquired Respiratory and Skin/Soft-Tissue Infections among Military Trainees. Clinical Infectious Diseases. 2004; 38(8): 1095-1101. PubMed | Google Scholar

  32. Chico RM and D. Chandramohan, Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011; 7(9): 1153-67. PubMed | Google Scholar

  33. Chico RM et al. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar J. 2008; 7:255. PubMed | Google Scholar

  34. Whitty CJ, GK, Sadiq ST, Mabey DC, Bailey R. Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr Infect Dis J. 1999 Nov;18(11):955-8. PubMed | Google Scholar

  35. Snow RW et al. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ. 1999; 77(8): 624-40. PubMed | Google Scholar

  36. Lopez AD et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367(9524): 1747-57. PubMed | Google Scholar

  37. WHO, World Health Organization. Malaria and HIV interactions and their implications for public health policy, 2004. Available at: http://www.who.int/hiv/pub/prev_care/malariahiv.pdf. Accessed October 27, 2012. 2004.

  38. Anderson, SL et al. Prophylaxis of Plasmodium falciparum Malaria with Azithromycin Administered to Volunteers. Annals of Internal Medicine. 1995; 123(10): 771-773. PubMed | Google Scholar

  39. Dunne, MW, et al. A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of plasmodium vivax malaria in india. Am J Trop Med Hyg. 2005; 73(6): 1108-1111. PubMed | Google Scholar

  40. Heppner, DG, JR et al. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of plasmodium vivax malaria in western Thailand. Am J Trop Med Hyg. 2005; 73(5): 842-849. PubMed | Google Scholar

  41. Miller, RS et al. Effective treatment of uncomplicated plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging studyabstract. Am J Trop Med Hyg. 2006; 74(3): 401-406. PubMed | Google Scholar

  42. Andersen SL, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis. 1998 Jan;26(1):146-50. PubMed | Google Scholar

  43. Sadiq, ST et al. Effects of azithromycin on malariometric indices in The Gambia. The Lancet. 1995; 346(8979): 881-882. PubMed | Google Scholar

  44. Taylor WR, et al. Tolerability of Azithromycin as Malaria Prophylaxis in Adults in Northeast Papua, Indonesia. Antimicrob Agents Chemother. 2003 July; 47(7): 2199-2203. PubMed | Google Scholar

  45. Wi T, RE, Steen R, Esguerra TA, Roces MCR, Lim-Quizon MC, Neilsen G, Dallabetta G, .STI declines among sex workers and clients following outreach, one time presumptive treatment, and regular screening of sex workers in the Philippines. Sex Transm Infect. 2006;82(5):386–391. PubMed | Google Scholar

&